

# Marion Saville

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231322/publications.pdf>

Version: 2024-02-01

54  
papers

1,853  
citations

279487

23  
h-index

264894

42  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1969  
citing authors

#	ARTICLE	IF	CITATIONS
1	The experience of under-screened and never-screened participants using clinician-supported self-collection cervical screening within the Australian National Cervical Screening Program. <i>Women's Health</i> , 2022, 18, 174550652210759.	0.7	6
2	Reasons for rejection of self-collected samples for cervical screening. <i>Medical Journal of Australia</i> , 2022, 216, 214-214.	0.8	2
3	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. <i>BMJ, The</i> , 2022, 376, e068582.	3.0	16
4	HPV self-sampling and follow-up over two rounds of cervical screening in Australia – the iPap trial. <i>Journal of Medical Screening</i> , 2022, 29, 185-193.	1.1	3
5	Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea. <i>BMJ Global Health</i> , 2022, 7, e007380.	2.0	13
6	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 268-277.	1.1	24
7	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. <i>Preventive Medicine</i> , 2021, 144, 106293.	1.6	10
8	Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era. <i>Preventive Medicine</i> , 2021, 144, 106294.	1.6	25
9	Self-collection cervical screening in the renewed National Cervical Screening Program: a qualitative study. <i>Medical Journal of Australia</i> , 2021, 215, 354-358.	0.8	23
10	The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support. <i>International Journal of Cancer</i> , 2021, 149, 1997-2009.	2.3	11
11	Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. <i>Vaccine</i> , 2020, 38, 1186-1193.	1.7	8
12	HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. <i>Vaccine</i> , 2020, 38, 6304-6311.	1.7	9
13	Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard. <i>Vaccine</i> , 2020, 38, 6312-6319.	1.7	5
14	Self-Collection for Cervical Screening Programs: From Research to Reality. <i>Cancers</i> , 2020, 12, 1053.	1.7	46
15	Uptake and acceptability of human papillomavirus self-sampling in rural and remote aboriginal communities: evaluation of a nurse-led community engagement model. <i>BMC Health Services Research</i> , 2020, 20, 398.	0.9	24
16	The value of data linkage depends on the quality of the data: incorporating Medicare data alters cervical screening analysis findings. <i>Medical Journal of Australia</i> , 2020, 212, 383-383.	0.8	1
17	Compliance with follow-up Test of Cure and outcomes after treatment for high-grade cervical intraepithelial neoplasia in Victoria, Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 433-437.	0.4	5
18	Title is missing!. , 2020, 15, e0228042.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0228042.		0
20	Title is missing!. , 2020, 15, e0228042.		0
21	Title is missing!. , 2020, 15, e0228042.		0
22	Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100177.	4.5	78
23	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	0.6	14
24	Age-specific HPV prevalence among 116,052 women in Australiaâ€™s renewed cervical screening program: A new tool for monitoring vaccine impact. Vaccine, 2019, 37, 412-416.	1.7	35
25	Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?. International Journal of Cancer, 2019, 144, 2964-2971.	2.3	14
26	The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health, The, 2019, 4, e19-e27.	4.7	268
27	Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Research and Practice, 2019, 29, .	0.7	41
28	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25â€“69 years living in Australia. BMJ Open, 2018, 8, e016700.	0.8	20
29	Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Research (Amsterdam, Netherlands), 2018, 6, 70-76.	4.5	32
30	Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs. Journal of the American Society of Cytopathology, 2018, 7, 336-338.	0.2	1
31	<i>â€˜Lest we forgetâ€™</i> as we move forward with cervical screening. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 265-266.	0.4	1
32	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017â€“2035: Example from Australia. PLoS ONE, 2018, 13, e0185332.	1.1	52
33	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health, The, 2017, 2, e96-e107.	4.7	124
34	Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. International Journal of Cancer, 2017, 141, 1576-1584.	2.3	51
35	Cost-effectiveness estimates: the need for complete reporting â€“ Authors' reply. Lancet Public Health, The, 2017, 2, e212.	4.7	2
36	Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health, The, 2017, 2, e331-e340.	4.7	114

#	ARTICLE	IF	CITATIONS
37	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002388.	3.9	67
38	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. <i>PLoS ONE</i> , 2017, 12, e0163509.	1.1	26
39	HPV vaccine impact in Australian women: ready for an HPV-based screening program. <i>Medical Journal of Australia</i> , 2016, 204, 184-184.	0.8	65
40	Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia. <i>International Journal of Cancer</i> , 2016, 139, 281-290.	2.3	80
41	Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. <i>BMC Health Services Research</i> , 2016, 16, 147.	0.9	36
42	Women's experience with home-based self-sampling for human papillomavirus testing. <i>BMC Cancer</i> , 2015, 15, 849.	1.1	81
43	Women's views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting. <i>Sexual Health</i> , 2015, 12, 279.	0.4	19
44	Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 59-73.	4.5	62
45	A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. <i>Journal of Clinical Virology</i> , 2015, 69, 210-213.	1.6	16
46	Cervical screening rates for women vaccinated against human papillomavirus. <i>Medical Journal of Australia</i> , 2014, 201, 279-282.	0.8	38
47	Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. <i>Sexually Transmitted Infections</i> , 2014, 90, 532-537.	0.8	9
48	Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey. <i>Vaccine</i> , 2014, 32, 592-597.	1.7	58
49	Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. <i>BMC Cancer</i> , 2014, 14, 207.	1.1	24
50	How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions. <i>Vaccine</i> , 2014, 32, 4082-4088.	1.7	15
51	Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). <i>BMC Cancer</i> , 2013, 13, 296.	1.1	20
52	Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. <i>Sexual Health</i> , 2011, 8, 171.	0.4	90
53	Mobile phones are a viable option for surveying young Australian women: a comparison of two telephone survey methods. <i>BMC Medical Research Methodology</i> , 2011, 11, 159.	1.4	22
54	Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention. <i>Vaccine</i> , 2008, 26, M80-M88.	1.7	47